Zimmer Biomet vs Boston Scientific

Zimmer Biomet and Boston Scientific are two leading companies in the medical device industry, both offering innovative products and solutions to improve patient outcomes. While Zimmer Biomet is known for its orthopedic implants and surgical tools, Boston Scientific specializes in cardiovascular, urology, and neurology devices. Investors looking to diversify their portfolio in the healthcare sector may consider comparing and analyzing the performance of Zimmer Biomet and Boston Scientific stocks to make informed investment decisions.

Zimmer Biomet or Boston Scientific?

When comparing Zimmer Biomet and Boston Scientific, different investors may prioritize various metrics based on their investment strategies and goals. So, ask yourself what type of investor you are. This will guide you in determining which metrics are most important for your investment decision between Zimmer Biomet and Boston Scientific.

Dividend Investors:

Dividend investors look for stable and growing income streams, using dividend metrics to assess potential investments. A company's dividend yield essentially measures the size of its dividend relative to the total market value of the company. Zimmer Biomet has a dividend yield of 0.69%, while Boston Scientific has a dividend yield of -%. Beyond the yield itself, considering the growth and sustainability of these dividends is also crucial. Zimmer Biomet reports a 5-year dividend growth of -12.94% year and a payout ratio of 19.97%. On the other hand, Boston Scientific reports a 5-year dividend growth of 0.00% year and a payout ratio of 0.00%.

Value Investors:

Value investors focus on financial metrics to determine a stock's intrinsic value compared to its market value. The Price-to-Earnings (P/E) Ratio links stock price to a company's earnings per share, with Zimmer Biomet P/E ratio at 21.58 and Boston Scientific's P/E ratio at 69.92. Another crucial valuation metric is the Price-to-Book (P/B) Ratio, which compares stock price with book value per share. Zimmer Biomet P/B ratio is 1.69 while Boston Scientific's P/B ratio is 6.26.

Growth Investors:

Growth investors prioritize metrics indicative of a company's expansion potential. Focusing on top-line growth, Zimmer Biomet has seen a 5-year revenue growth of -0.09%, while Boston Scientific's is 0.38%. Return on Equity (ROE) measures how effectively a company uses equity investment to generate earnings, with Zimmer Biomet's ROE at 7.92% and Boston Scientific's ROE at 9.30%.

Retail Investors:

Retail investors often consider stock affordability and company familiarity. For example, day low prices are $103.51 for Zimmer Biomet and $86.50 for Boston Scientific. Over the past year, Zimmer Biomet's prices ranged from $101.47 to $133.90, with a yearly change of 31.96%. Boston Scientific's prices fluctuated between $49.15 and $88.09, with a yearly change of 79.23%. Brand recognition also plays a role, as familiarity with a company can influence investment decisions.